NIH grants $4.1 million for artificial heart study
This article was originally published in The Gray Sheet
Executive Summary
Texas Heart Institute at St. Luke's Episcopal Hospital receives a $4.1 illion grant for a study to determine the effect of pulseless blood flow on bodily functions, the Houston-based research institution announces Aug. 18. The data will be used to develop a total artificial heart with continuous, pulseless blood flow that would fit even in small adults and be more durable than current heart replacement devices, lasting 10 years or more without replacement, THI explains. The research will be led by THI physician O.H. Frazier, with team members from Thoratec and Beth Israel Deaconess Medical Center/Harvard Medical School
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.